JPMorgan Chase & Co. set a €95.00 ($113.10) target price on Merck KGaA (FRA:MRK) in a research report sent to investors on Wednesday, January 10th. The firm currently has a neutral rating on the healthcare company’s stock.
Other analysts have also recently issued reports about the stock. Citigroup set a €123.00 ($146.43) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, September 13th. Berenberg Bank set a €116.00 ($138.10) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, September 13th. Kepler Capital Markets set a €119.00 ($141.67) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Thursday, September 21st. Warburg Research set a €115.00 ($136.90) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Tuesday, September 26th. Finally, UBS Group began coverage on shares of Merck KGaA in a research note on Tuesday, September 26th. They issued a buy rating and a €120.00 ($142.86) price objective for the company. Twelve investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of €107.57 ($128.06).
Shares of Merck KGaA (MRK) opened at €91.84 ($109.33) on Wednesday. The firm has a market cap of $11,990.00 and a P/E ratio of 21.51. Merck KGaA has a 1-year low of €87.33 ($103.96) and a 1-year high of €115.00 ($136.90).
WARNING: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2018/01/17/merck-kgaa-mrk-given-a-95-00-price-target-by-jpmorgan-chase-co-analysts.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.